Cardiometabolic biomarkers

PreclinicalBiologic

UUniversity of Hertfordshire

Cardiometabolic biomarkers is one of 6 biologic programs targeting Weight Management. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Weight ManagementCompleted

Weight ManagementPreclinical

Completed

Competition

Competitive Landscape

7 competitors in Weight Management

#DrugCompanyPhaseTrials

VK2735

VViking Therapeutics, Inc.

Phase 3

3 2

Prilosec

DDexcel Pharma Technologies Ltd.

Phase 1

1 3

HRS9531

FFujian Shengdi Pharmaceutical Co., Ltd.

Phase 1

1 4

Meridia

AAbbott

Preclinical

1 5

Cardiometabolic biomarkers

UUniversity of Hertfordshire

Preclinical

1 6

Febuxostat Tab

XXuhui Central Hospital, Shanghai

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Weight Management1 trial

Biomarker Feedback on Health and Wellbeing and Exercise Adherence Following a 6 Month Weight Management Course

Completed·UUniversity of Hertfordshire·N/A·NCT03809871·43 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cardiometabolic biomarkers. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cardiometabolic biomarkers compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cardiometabolic biomarkers. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Hertfordshire company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Hertfordshire

Cardiometabolic biomarkers

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Weight Management1 trial

References

Drug Info

Quick Facts

Related News